IPO - Aditxt, Inc.

Form Type: S-1

Filing Date: 2025-06-20

Corporate Action: Ipo

Type: New

Accession Number: 000121390025056288

Filing Summary: Aditxt, Inc. filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission on June 20, 2025, to register up to 50,000,000 shares of common stock for resale, which may be issued to Seven Knots, LLC under a common stock purchase agreement. The total purchase commitment from Seven Knots is $150,000,000, with prior sales yielding approximately $23.9 million from 932,549 shares. Aditxt's common stock is traded on The Nasdaq Capital Market under the symbol 'ADTX'. The document details Aditxt's business model centered around enabling innovations in health care, including initiatives such as the development of immune modulation therapies and personalized medicine through its subsidiaries. The company is categorized as a smaller, emerging growth company and aims to publicize its subsidiaries, including Pearsanta, which is positioned to go public potentially in 2025. The prospectus outlines the strategic goals in advancing medical technologies, acquiring relevant assets, and establishing collaborations with research institutions and healthcare providers.

Form Type: 8-K

Filing Date: 2025-01-13

Corporate Action: Ipo

Type: New

Accession Number: 000121390025002846

Filing Summary: On January 13, 2025, Aditxt, Inc. announced that its Board of Directors has authorized management to explore taking its subsidiary, Pearsanta, Inc., public through a proposed initial public offering (IPO) in 2025. The company indicated that there is no assurance the IPO will take place, as it is undertaking preliminary measures and requires Board approval. The decision is also subject to market conditions. Forward-looking statements are included in the report, outlining risks and uncertainties that may affect the IPO's success.